Cargando…

Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study

BACKGROUND: To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (hereafter, TACE-RFA) in treating Barcelona Clinic Liver Cancer (BCLC) Stage A or B (hereafter, BCLC A/B) hepatocellular carcinoma (HCC) patients, and to explore the range...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Yanqiao, Cao, Yanyan, Ma, Hong, Kan, Xuefeng, Zhou, Chen, Liu, Jiacheng, Shi, Qin, Feng, Gansheng, Xiong, Bin, Zheng, Chuansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805486/
https://www.ncbi.nlm.nih.gov/pubmed/31640620
http://dx.doi.org/10.1186/s12885-019-6237-5
_version_ 1783461396349976576
author Ren, Yanqiao
Cao, Yanyan
Ma, Hong
Kan, Xuefeng
Zhou, Chen
Liu, Jiacheng
Shi, Qin
Feng, Gansheng
Xiong, Bin
Zheng, Chuansheng
author_facet Ren, Yanqiao
Cao, Yanyan
Ma, Hong
Kan, Xuefeng
Zhou, Chen
Liu, Jiacheng
Shi, Qin
Feng, Gansheng
Xiong, Bin
Zheng, Chuansheng
author_sort Ren, Yanqiao
collection PubMed
description BACKGROUND: To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (hereafter, TACE-RFA) in treating Barcelona Clinic Liver Cancer (BCLC) Stage A or B (hereafter, BCLC A/B) hepatocellular carcinoma (HCC) patients, and to explore the range of tumor sizes suitable for combination therapy. METHODS: This retrospective study assessed the consecutive medical records of HCC patients with BCLC A/B who received TACE-RFA or TACE from September 2009 to September 2018. Progression-free survival (PFS), overall survival (OS), therapeutic response, and complications were compared between the two groups. RESULTS: Among 2447 patients who received TACE-RFA or TACE, 399 eligible patients were enrolled in our study, including 128 patients in the TACE-RFA group and 271 patients in the TACE group. Compared with the TACE group, the PFS and OS rates of 1,3,5,8 years in the TACE-RFA group were significantly better, with higher objective tumor regression rate and better disease control rate. RFA treatment did not increase the risk of death in patients with HCC, and both liver subcapsular hematoma and bile duct injury were improved by symptomatic treatment. Serum α-fetoprotein level and treatment method were important independent prognostic factors for OS, whereas albumin, hepatitis B and treatment method were important independent prognostic factors for PFS. Subgroup analysis showed that patients in the TACE-RFA group always showed better OS and PFS. CONCLUSIONS: TACE-RFA had an advantage over TACE alone in prolonging PFS and improving OS in HCC patients with BCLC A/B, and can benefit patients regardless of tumor size.
format Online
Article
Text
id pubmed-6805486
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68054862019-10-24 Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study Ren, Yanqiao Cao, Yanyan Ma, Hong Kan, Xuefeng Zhou, Chen Liu, Jiacheng Shi, Qin Feng, Gansheng Xiong, Bin Zheng, Chuansheng BMC Cancer Research Article BACKGROUND: To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with radiofrequency ablation (hereafter, TACE-RFA) in treating Barcelona Clinic Liver Cancer (BCLC) Stage A or B (hereafter, BCLC A/B) hepatocellular carcinoma (HCC) patients, and to explore the range of tumor sizes suitable for combination therapy. METHODS: This retrospective study assessed the consecutive medical records of HCC patients with BCLC A/B who received TACE-RFA or TACE from September 2009 to September 2018. Progression-free survival (PFS), overall survival (OS), therapeutic response, and complications were compared between the two groups. RESULTS: Among 2447 patients who received TACE-RFA or TACE, 399 eligible patients were enrolled in our study, including 128 patients in the TACE-RFA group and 271 patients in the TACE group. Compared with the TACE group, the PFS and OS rates of 1,3,5,8 years in the TACE-RFA group were significantly better, with higher objective tumor regression rate and better disease control rate. RFA treatment did not increase the risk of death in patients with HCC, and both liver subcapsular hematoma and bile duct injury were improved by symptomatic treatment. Serum α-fetoprotein level and treatment method were important independent prognostic factors for OS, whereas albumin, hepatitis B and treatment method were important independent prognostic factors for PFS. Subgroup analysis showed that patients in the TACE-RFA group always showed better OS and PFS. CONCLUSIONS: TACE-RFA had an advantage over TACE alone in prolonging PFS and improving OS in HCC patients with BCLC A/B, and can benefit patients regardless of tumor size. BioMed Central 2019-10-22 /pmc/articles/PMC6805486/ /pubmed/31640620 http://dx.doi.org/10.1186/s12885-019-6237-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ren, Yanqiao
Cao, Yanyan
Ma, Hong
Kan, Xuefeng
Zhou, Chen
Liu, Jiacheng
Shi, Qin
Feng, Gansheng
Xiong, Bin
Zheng, Chuansheng
Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study
title Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study
title_full Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study
title_fullStr Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study
title_full_unstemmed Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study
title_short Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study
title_sort improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in barcelona clinic liver cancer stage a or b hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805486/
https://www.ncbi.nlm.nih.gov/pubmed/31640620
http://dx.doi.org/10.1186/s12885-019-6237-5
work_keys_str_mv AT renyanqiao improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT caoyanyan improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT mahong improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT kanxuefeng improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT zhouchen improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT liujiacheng improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT shiqin improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT fenggansheng improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT xiongbin improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy
AT zhengchuansheng improvedclinicaloutcomeusingtransarterialchemoembolizationcombinedwithradiofrequencyablationforpatientsinbarcelonacliniclivercancerstageaorbhepatocellularcarcinomaregardlessoftumorsizeresultsofasinglecenterretrospectivecasecontrolstudy